|
|
|
|
| LEADER |
03110nam a2200817Ia 4500 |
| 001 |
10.18553-jmcp.2021.27.2.137 |
| 008 |
220427s2021 CNT 000 0 und d |
| 020 |
|
|
|a 23760540 (ISSN)
|
| 245 |
1 |
0 |
|a Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree
|
| 260 |
|
0 |
|b Academy of Managed Care Pharmacy (AMCP)
|c 2021
|
| 856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.18553/jmcp.2021.27.2.137
|
| 520 |
3 |
|
|a BACKGROUND: The hepatitis C virus (HCV) prevalence rate among injection drug users (IDUs) in North America is 55.2%, with 1.41 million individuals estimated to be HCV-antibody positive. Studies have shown the effectiveness of syringe service programs (SSPs) alone, medications for opioid use disorder (MOUD) alone, or SSP+MOUD combination in reducing HCV transmission among opioid IDUs. OBJECTIVE: To evaluate the cost-effectiveness of SSP alone, MOUD alone, and SSP+MOUD combination in preventing HCV cases among opioid IDUs in the United States.
|
| 650 |
0 |
4 |
|a adverse event
|
| 650 |
0 |
4 |
|a Analgesics, Opioid
|
| 650 |
0 |
4 |
|a antiviral therapy
|
| 650 |
0 |
4 |
|a antivirus agent
|
| 650 |
0 |
4 |
|a Article
|
| 650 |
0 |
4 |
|a complication
|
| 650 |
0 |
4 |
|a cost benefit analysis
|
| 650 |
0 |
4 |
|a cost control
|
| 650 |
0 |
4 |
|a cost effectiveness analysis
|
| 650 |
0 |
4 |
|a Cost-Benefit Analysis
|
| 650 |
0 |
4 |
|a decision tree
|
| 650 |
0 |
4 |
|a Decision Trees
|
| 650 |
0 |
4 |
|a drug use
|
| 650 |
0 |
4 |
|a Drug Users
|
| 650 |
0 |
4 |
|a economics
|
| 650 |
0 |
4 |
|a harm reduction
|
| 650 |
0 |
4 |
|a harm reduction
|
| 650 |
0 |
4 |
|a Harm Reduction
|
| 650 |
0 |
4 |
|a health care cost
|
| 650 |
0 |
4 |
|a health program
|
| 650 |
0 |
4 |
|a health service
|
| 650 |
0 |
4 |
|a hepatitis C
|
| 650 |
0 |
4 |
|a hepatitis C
|
| 650 |
0 |
4 |
|a Hepatitis C
|
| 650 |
0 |
4 |
|a high risk behavior
|
| 650 |
0 |
4 |
|a human
|
| 650 |
0 |
4 |
|a Humans
|
| 650 |
0 |
4 |
|a injection drug user
|
| 650 |
0 |
4 |
|a major clinical study
|
| 650 |
0 |
4 |
|a medical decision making
|
| 650 |
0 |
4 |
|a narcotic analgesic agent
|
| 650 |
0 |
4 |
|a needle sharing
|
| 650 |
0 |
4 |
|a Needle Sharing
|
| 650 |
0 |
4 |
|a Needle-Exchange Programs
|
| 650 |
0 |
4 |
|a opiate
|
| 650 |
0 |
4 |
|a opiate addiction
|
| 650 |
0 |
4 |
|a opiate addiction
|
| 650 |
0 |
4 |
|a opiate substitution treatment
|
| 650 |
0 |
4 |
|a Opiate Substitution Treatment
|
| 650 |
0 |
4 |
|a Opioid-Related Disorders
|
| 650 |
0 |
4 |
|a organization and management
|
| 650 |
0 |
4 |
|a prevalence
|
| 650 |
0 |
4 |
|a Prevalence
|
| 650 |
0 |
4 |
|a preventive health service
|
| 650 |
0 |
4 |
|a psychology
|
| 650 |
0 |
4 |
|a quality adjusted life year
|
| 650 |
0 |
4 |
|a Quality-Adjusted Life Years
|
| 650 |
0 |
4 |
|a risk behavior
|
| 650 |
0 |
4 |
|a Risk-Taking
|
| 650 |
0 |
4 |
|a sensitivity analysis
|
| 650 |
0 |
4 |
|a substance abuse
|
| 650 |
0 |
4 |
|a Substance Abuse, Intravenous
|
| 650 |
0 |
4 |
|a United States
|
| 650 |
0 |
4 |
|a United States
|
| 700 |
1 |
|
|a Carroll, N.V.
|e author
|
| 700 |
1 |
|
|a Holdford, D.A.
|e author
|
| 700 |
1 |
|
|a Ijioma, S.C.
|e author
|
| 700 |
1 |
|
|a Pontinha, V.M.
|e author
|
| 773 |
|
|
|t Journal of Managed Care and Specialty Pharmacy
|
